Mercury Laboratories Ltd (MERCURYLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Mercury Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Mercury Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 05 Nov 2026, 5:30 am
Mercury Laboratories Board Meeting Scheduled for Nov'26 Financial Results Mercury Laboratories Limited has scheduled a Board of Directors meeting on 5th Nov'26 to consider and approve the company's unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the insider trading window has been closed effective 1st Oct'26 and will reopen 48 hours following the formal declaration of the financial results.
Intimation for cessation of HR manager
Change in Management · 29 Oct 2026, 12:20 am
Mercury Laboratories Announces Cessation of HR Manager Jaydeepsinh Raj Mercury Laboratories Limited announced the cessation of Senior Management Personnel Mr. Jaydeepsinh Raj, Manager-HR, effective 28th Oct'26. The cessation occurred as the employee discontinued reporting for duty without prior notice or following prescribed formal communication procedures. The company confirmed there are no other material reasons for the exit and is currently undertaking the necessary internal formalities.
Intimation regarding cessation of director upon conclusion of AGM
Change in Management · 01 Oct 2026, 1:04 am
Submission of voting results of the 45th AGM of the Company alongwith scrutinizers report thereon
Annual General Meeting · 30 Sept 2026, 11:49 pm
Proceeding of the 45th AGM of the Company is attched
Annual General Meeting · 28 Sept 2026, 6:07 pm
Intimation for appointment of Manager HR as senior Management is attched
Change in Management · 03 Sept 2026, 11:49 pm
Mercury Laboratories Appoints Jaydeepsinh Raj as New Manager-HR Mercury Laboratories Limited (BSE: 538964) appointed Jaydeepsinh Raj as Manager-HR, effective 3rd Sep'26, officially classifying him as Senior Management Personnel. Raj brings over eight years of comprehensive HR experience, specializing in employee relations, talent management, and recruitment operations. He holds a Bachelor’s degree in Social Work and previously held HR roles at IDMC Limited and Sudeep Pharma Private Limited. The full-time appointment introduces new leadership to the company's human resources division, with no disclosed familial relationships to existing board directors.
Please find enclosed herewith a copy of 45th Annual Report of the Company for the Financial Year ended March 31, 2026.
Others (Uncategorized) · 01 Sept 2026, 11:14 pm
Please find enclosed herewith a copy of 45th AGM notice of the Company scheduled to be held on 28/09/2026 at 11.30 AM IST
Annual General Meeting · 01 Sept 2026, 11:06 pm
Intimation regarding appointment of Mr. Sunil Sharma and resignation of Ms. Seema Salvi as HOD injectable
Change in Management · 21 Aug 2026, 8:02 pm
Mercury Labs Appoints New Head of Injectable Production Mercury Laboratories has appointed Mr. Sunil Sharma as the new Head of Department (Injectable Production), effective 21 Aug'26. He succeeds Ms. Seema Salvi, who resigned from the same role to pursue better career opportunities. Mr. Sharma brings over 19 years of experience in injection production, having previously worked at Sun Pharma, Intas Pharmaceuticals, Bharat Parentals, and Flagship Biotech International. He holds a Bachelor's degree in Pharmacy and is approximately 45 years old. This change affects a key production division for the company.
Communication to Shareholders on TDS on the dividend for the FY 25-26 is attached
Dividend · 20 Aug 2026, 11:27 pm
Mercury Laboratories Announces FY26 Dividend and Sets Record Date Mercury Laboratories' board has recommended a dividend of Rs. 3.5 per share (35%) for FY ended 31 Mar'26, on a face value of Rs. 10. The proposal is subject to shareholder approval at the upcoming AGM. The company has fixed 21 Sep'26 as the record date for determining dividend eligibility. As per current tax laws, the dividend is taxable in shareholders' hands, and the company will deduct tax at source (TDS) at applicable rates before payment. Deadlines for submitting tax exemption documents is also 21 Sep'26.
Unaudited Financial results for the quarter ended on June 30, 2026 is attched
Financial Result · 25 Jul 2026, 5:51 pm
Mercury Laboratories Q1FY27 Net Profit Declines 69% YoY Amid Lower Revenue Mercury Laboratories reported a significant decline for Q1FY27, with Net Profit falling 69.3% YoY to ₹29.78 lakhs from ₹96.76 lakhs. Revenue from Operations decreased by 12.0% YoY to ₹1,596.32 lakhs. The profit decline was even steeper sequentially, down 75.7% QoQ from ₹122.54 lakhs. Total expenses remained relatively flat YoY at ₹1,562.35 lakhs. Basic and Diluted EPS for the quarter stood at ₹2.48, a sharp drop from ₹8.06 in the same quarter last year and ₹10.21 in the preceding quarter.
Outcome of meeting for approval of the unaudited financial statement for the quarter ended on June 30, 2026 is attched
Outcome · 25 Jul 2026, 5:45 pm
Mercury Labs Q1FY27 Net Profit Plummets 69.2% YoY Amid Revenue Decline Mercury Laboratories reported a 69.2% YoY decline in Net Profit to ₹29.78 lakhs for Q1FY27, down from ₹96.76 lakhs in Q1FY26. Revenue from Operations fell 11.9% YoY to ₹1,596.32 lakhs. On a QoQ basis, revenue dropped 21.9% and net profit plunged 75.7%. Total expenses decreased by a smaller margin of 6.8% YoY to ₹1,562.35 lakhs, failing to offset the sharp revenue contraction. Consequently, Basic EPS for the quarter fell significantly to ₹2.48 from ₹8.06 a year ago.
Mercury Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 25 Jul 2026, 5:30 am
Mercury Labs Board to Review Q1 FY27 Results on 25 Jul'26 Mercury Laboratories Ltd. has scheduled a Board of Directors meeting on 25 Jul'26 to consider and approve the Unaudited Financial Results for the quarter ended 30 Jun'26. In accordance with insider trading regulations, the trading window for designated persons has been closed from 01 Jul'26 and will reopen 48 hours after the financial results are declared.
Intimation regarding Credit Rating on Fixed deposit is attached
Others (Uncategorized) · 01 Jul 2026, 9:55 pm
CRISIL Reaffirms Mercury Laboratories' Fixed Deposit Rating at BB+/Stable CRISIL Ratings reaffirmed its 'CRISIL BB+/Stable' rating for Mercury Laboratories Limited's INR 3 Cr fixed deposit program on 30-Jun'26. This rating signifies a moderate risk of default regarding the timely servicing of financial obligations. The rating and outlook are subject to continuous surveillance by the agency. Mercury Laboratories disclosed this reaffirmation to the BSE on 01-Jul'26.
Intimation about the appointment of Plant head is attached
Change in Management · 11 Jun 2026, 8:03 pm
Mercury Laboratories Appoints New Plant Head for Jarod Unit Mercury Laboratories has appointed Mr. Binaya Kumar Panigrahi as Plant Head of its Jarod Unit, effective 11 Jun'26. This full-time appointment designates him as Senior Management Personnel (SMP). Mr. Panigrahi, 52, holds a B.Pharm degree and has over 24 years of experience in tablet manufacturing. His previous roles were with Coral Laboratories Limited and Biocon Biological India Limited. He has no relationships with the company's existing directors.
Corrigendum to audited financial statement results for the quarter and year ended on 31.03.2026 is attached
Others (Uncategorized) · 30 May 2026, 12:27 am
Mercury Labs FY26 Net Profit Jumps 53.7% YoY; Corrected Financials Submitted Mercury Laboratories reported a net profit of ₹483.40 lakhs for FY26, a 53.7% YoY increase from ₹314.49 lakhs. Revenue from operations grew marginally to ₹7,593.67 lakhs. For Q4 FY26, net profit was ₹122.54 lakhs, up 10.4% YoY. The company resubmitted its financial results on 29 May'26 to correct prior errors in current liabilities and cash flow statements. The Board recommended a final dividend of ₹3.50 per share (35%). Full-year EPS stood at ₹40.28, up from ₹26.21 in FY25.
Details of Appointment of Internal Auditor and Cost auditor is attached
Change in Management · 29 May 2026, 8:25 pm
Mercury Laboratories Appoints Auditors for FY 2026-27 Mercury Laboratories' Board approved key auditor appointments on 29 May'26. The company has re-appointed M/s K R & Associates (Vadodara) as its Internal Auditor and M/s V. M. Patel & Associates (Surat) as its Cost Auditor. Both appointments are for the financial year 2026-27, ensuring continuity in the company's audit and compliance functions.
book colusre intimation for 45th AGM and Dividend is attached
Annual General Meeting · 29 May 2026, 8:22 pm
Mercury Laboratories Announces Dividend Record Date and AGM Mercury Laboratories (BSE: 538964) has announced a final dividend of Rs. 3.5 per equity share (35.00%). The company has set Monday, 21st Sep'26 as the record date to determine shareholder eligibility for the dividend payment. The Register of Members will be closed from 22nd Sep'26 to 28th Sep'26. The 45th Annual General Meeting (AGM), where the dividend will be subject to shareholder approval, is scheduled for Monday, 28th Sep'26.
Recommendation of Dividend by the Board for the FY 2025-26
Dividend · 29 May 2026, 8:12 pm
Mercury Labs FY26 Net Profit Rises 54% YoY, Recommends Rs 3.50 Dividend Mercury Laboratories reported a 53.7% YoY increase in net profit to ₹483.40 lakhs for FY26, with revenue from operations growing marginally to ₹7,593.67 lakhs. For Q4 FY26, net profit rose 10.4% YoY to ₹122.54 lakhs on revenue of ₹2,044.24 lakhs. The Board recommended a final dividend of 35% (₹3.50 per share) for FY26. The record date for the dividend payment is set for 21 Sep'26, subject to shareholder approval at the AGM on 28 Sep'26. Basic EPS for FY26 stood at ₹40.28.
Audited Financial results for the year ended on March 31, 2026 along with auditors report is attached
Financial Result · 29 May 2026, 8:04 pm
Mercury Laboratories Reports FY26 Results and Declares Dividend Mercury Laboratories reported FY26 Net Profit After Tax of ₹483.40 lakhs, a 53.7% YoY increase. Revenue from operations grew marginally to ₹7,593.67 lakhs from ₹7,510.12 lakhs. For Q4FY26, PAT was ₹122.54 lakhs, up 10.4% YoY. The Board recommended a final dividend of 35% (₹3.50 per share) for FY26. The record date for the dividend is set for 21 Sep'26, and the 45th Annual General Meeting will be held on 28 Sep'26. The auditor issued an unmodified opinion on the financial results.
Outocme of Board Meeting held on May 29, 2025 is attached
Outcome · 29 May 2026, 7:57 pm
Mercury Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 2,044 (-1.0% YoY | +11.4% QoQ) ■ EBITDA: 204 (-3.9% YoY | -19.0% QoQ) ■ EBITDA Margin (%): 10.0 (-30 bps YoY | -375 bps QoQ) ■ PAT: 123 (+10.4% YoY | +22.8% QoQ) ■ EPS (INR): 10.2 (+10.4% YoY | +22.9% QoQ)
Mercury Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Intimation · 29 May 2026, 5:30 am
Mercury Laboratories Board Meeting Set for Audited FY26 Results and Dividend Mercury Laboratories (BSE: 538964) will hold a Board of Directors meeting on 29 May'26 to consider and approve audited financial results for the quarter and year ended 31 Mar'26. The board will also consider a dividend recommendation for FY26, subject to shareholder approval at the upcoming Annual General Meeting. In compliance with insider trading regulations, the trading window for designated persons has been closed from 01 Apr'26 and will reopen 48 hours after the financial results are declared.
Intimation to shareholder relating to transfer of Equity shares to IEPFA is attached
Others (Uncategorized) · 07 May 2026, 8:22 pm
Mercury Laboratories Intimates Mandatory Share Transfer to IEPF Mercury Laboratories has notified shareholders of the impending transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority. This action affects shares for which dividends have remained unclaimed for seven consecutive years, starting from FY19. Shareholders must claim their unpaid dividends on or before 02 Nov '26 to prevent the transfer. The company issued the formal notice on 07 May '26, complying with SEBI regulations. Once transferred, shareholders can only reclaim shares by filing form IEPF-5 with the Authority.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 29 Apr 2026, 5:36 pm
Mercury Labs: No Mandatory Debt Borrowing for FY26 Mercury Laboratories Limited disclosed it has no mandatory borrowing requirement through debt securities for FY 2025-26. The company reported NIL incremental borrowing for the period, resulting in a NIL obligation for raising 25% of borrowings via debt instruments. Consequently, there was no actual borrowing through debt securities and no shortfall. This disclosure, dated 29 Apr'26, confirms the company was not identified as a Large Corporate (LC) requiring such mandatory borrowings for the specified fiscal year.
Intimation of Resignation of SM Plant head jarod attched
Change in Management · 29 Apr 2026, 5:25 pm
Mercury Laboratories' Plant Head-Jarod, Sandip Patel, Resigns Mercury Laboratories announced the resignation of Mr. Sandip Patel, Plant Head-Jarod and Senior Management Personnel (SMP), effective from the close of business hours on 28 Apr'26. The company stated the reason for the resignation is for better opportunities and career advancement. There were no other material reasons disclosed for his departure. This change in key operational leadership is a reportable event under SEBI's LODR Regulations.